Glioma - Pipeline Insight, 2022

Glioma - Pipeline Insight, 2022

DelveInsight’s, “Glioma - Pipeline Insight, 2022,” report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Glioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Glioma Understanding

Glioma: Overview

Glioma is the most common form of central nervous system (CNS) neoplasm that originates from glial cells. In the United States, there are six cases of gliomas diagnosed per 100,000 people every year. Gliomas are very diffusely infiltrative tumors that affect the surrounding brain tissue. Glioblastoma is the most malignant type while pilocytic astrocytomas are the least malignant brain tumors. In the past, these diffuse gliomas were classified into different subtypes and grades based on histopathologies such as a diffuse astrocytoma, oligodendrogliomas, or mixed gliomas/oligoastrocytomas. Recently, gliomas were classified based on molecular and genetic markers. These advances have more specific prognostic and therapeutic benefits for patients with gliomas. In addition to molecular and genetic markers, gliomas are classified in grade I to IV based on the degree of proliferation indicated by the mitotic index and the presence or absence of necrosis. There are three common types of gliomas, which are classified based on the phenotypic cell characteristics: astrocytomas, ependymomas, and oligodendrogliomas. These cell gliomas are further classified to low grade, atypical, and high-grade tumors based on cell morphology, mitotic activities, and molecular marker. The World Health Organization (WHO) grading system utilizes molecular markers that have shown to have significant prognostic and therapeutic implications. There is an estimation of 80,000 newly diagnosed cases of primary brain tumor each year in the United States. Around one-fourth of which (i.e. 20,000) are gliomas. The total number of glioblastomas diagnosed each year is around 12,000 cases (approximately 15% of total newly diagnosed brain tumors). Gliomas in general, specifically glioblastomas, are very difficult to treat. Despite advances in understanding the molecular biology and genetics of gliomas, no significant impact has been made toward preventing the lethality of high-grade gliomas. Therefore, there is a continuing need for clinical and basic science investigations to advance the care of this lethal disease.

""Glioma - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Glioma pipeline landscape is provided which includes the disease overview and Glioma treatment guidelines. The assessment part of the report embraces, in depth Glioma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glioma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Glioma.
• In the coming years, the Glioma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Glioma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Glioma treatment market. Several potential therapies for Glioma are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Glioma market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Glioma) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Glioma Emerging Drugs Chapters

This segment of the Glioma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Glioma Emerging Drugs

• ONC 201: Chimerix

ONC201 is the founding member of the imipridone class of anti-cancer small molecules which selectively targets Dopamine Receptor D2 (DRD2) and ClpP. ONC201-mediated cell death occurs via induction of the integrated stress response and upregulation of apoptotic factors, such as tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). It is dosed orally and has been well-tolerated and shown clinical activity in Phase I and II trials for specific advanced cancers. Clinical trials of ONC201 in glioma patients with the H3 K27M-mutation are underway at several locations in the U.S.

• DSP-7888: Sumitomo Dainippon Pharma

Ombipepimut-S Emulsion (DSP-7888) is an investigational WT1 immunotherapeutic cancer vaccine containing two peptides that induce WT1-specific cytotoxic T-lymphocytes (WT1-CTL) and helper T-cells to attack WT1-expressing cancerous cells found in various types of hematologic and solid tumors. Researchers have identified that adding a peptide to induce helper T cells may improve outcomes compared to a treatment regimen based on a killer peptide alone. Currently, it is in Phase III stage of clinical trial evaluation to treat Glioblastoma multiforme.

• AV-GBM-1: AIVITA Biomedical

AV-GBM-1 is a novel immunotherapy consisting of autologous dendritic cells loaded with autologous tumor antigens derived from self-renewing tumor-initiating cells. The treatment is administered in a series of subcutaneous injections. The treatment is uniquely pan-antigenic, targeting multiple antigens from autologous tumor-initiating cells that are responsible for the rapid growth of the disease.

• DB102: Denovo Biopharma

Lilly conducted many clinical studies with enzastaurin in a variety of tumor indications, including Phase 3 clinical trials in diffuse large B cell lymphoma (DLBCL) and glioma (GBM), and has received orphan drug certification in the U.S. and Europe. Denovo acquired global rights to enzastaurin from Lilly, including development, production and commercialization. Denovo has completed the identification of the biomarker, which is significantly correlated with the expected therapeutic effects on DLBCL and GBM patients, and has filed international patent applications. Denovo initiated a pivotal Phase 3 global DLBCL clinical trial in 2018 with data readout expected in mid-2022. In 2018 Denovo licensed the rights to use DB102 for Pulmonary Arterial Hypertension (PAH) from Stanford University.

• AB-218: AnHeart Therapeutics

AB-218 is a mIDH1 inhibitor that has reported blood brain barrier penetration for multiple solid tumors with mIDH1 mutations. Phase 1 clinical trials of AB-218 in glioma patients have demonstrated promising efficacy and safety profiles in 12 non-enhancing and 35 enhancing glioma patients. The objective response rate (ORR) was 33% and 17.1% in non-enhancing and enhancing patients, respectively.

Further product details are provided in the report……..

Glioma: Therapeutic Assessment

This segment of the report provides insights about the different Glioma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Glioma

There are approx. 150+ key companies which are developing the therapies for Glioma. The companies which have their Glioma drug candidates in the most advanced stage, i.e. phase II include, Chimerix.

• Phases

DelveInsight’s report covers around 150+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Glioma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Glioma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glioma drugs.

Glioma Report Insights

• Glioma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Glioma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Glioma drugs?
• How many Glioma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Glioma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glioma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Glioma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Chimerix
• Sumitomo Dainippon Pharma
• AIVITA Biomedical
• Denovo Biopharma
• Plus Therapeutics
• Philogen S.p.A.
• Xennials Therapeutics
• Laminar Pharmaceuticals
• Shanghai Gencells Therapeutics
• AnHeart Therapeutics Inc.
• Istari Oncology, Inc.
• Beijing Pearl Biotechnology Limited Liability Company
• Epitopoietic Research Corporation
• Everfront Biotech Co., Ltd.
• CNS Pharmaceuticals
• Bexion Pharmaceuticals, Inc.
• Lee's Pharmaceutical Limited
• Merck & Co
• Oblato, Inc.
• OncoSynergy, Inc.
• SystImmune
• Aadi Bioscience, Inc.
• Day One Biopharmaceuticals
• SpringWorks Therapeutics, Inc.
• Bristol-Myers Squibb
• PTC Therapeutics
• Apices Soluciones S.L.
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• TCRCure Biopharma
• SonALAsense, Inc.
• Midatech Pharma US Inc.
• Prelude Therapeutics
• Incyte Corporation
• BioMimetix JV, LLC
• GlaxoSmithKline
• DNAtrix
• Oblato, Inc.
• NeoImmuneTech
• Nuvation Bio Inc.
• Forma Therapeutics
• NanoPharmaceuticals LLC
• Erimos Pharmaceuticals
• Alaunos Therapeutics
• Symphogen
• Samus Therapeutics, Inc.
• Istari Oncology
• Neonc Technologies, Inc.
• Agios Pharmaceuticals
• Basilea Pharmaceutica
• BeiGene
• Kazia Therapeutics
• AstraZeneca
• Nerviano Medical Sciences
• VBL Therapeutics

Key Products

• ONC 201
• DSP-7888
• AV-GBM-1
• DB102
• BGB-290
• BAL101553
• Rhenium Nanoliposomes
• GDC-0084
• D2C7-IT
• Perillyl alcohol
• NMS-03305293
• Selumetinib
• Terameprocol
• Icapamespib
• Sym004
• Niraparib
• ivosidenib
• Ad-RTS-hIL-12
• BMX-001
• DNX-2401
• fb-PMT
• FT-2102
• OKN-007
• NUV-422
• rhIL-7-hyFc
• Anlotinib hydrochloride
• Histone H3.3-K27M
• Epacadostat
• PRT811
• AloCELYVIR
• MTX110
• SONALA-001
• PTC596
• Nivolumab
• L19TNF
• NTX-301
• Mirdametinib
• 2-OHOA
• Tumor Infiltrating Lymphocytes
• AB-218
• PVSRIPO
• PLB1001
• ERC1671
• Cerebraca wafer
• Berubicin Hydrochloride
• BXQ-350
• TG02
• Pembrolizumab
• OKN-007
• OS2966
• GNC-039
• ABI-009
• DAY101
• VB 111


Please Note: It will take 7-10 business days to complete the report upon order confirmation.